Menu
Search
|

Menu

Close
X

Merrimack Pharmaceuticals Inc MACK.OQ (NASDAQ Stock Exchange Global Market)

5.30 USD
-0.03 (-0.56%)
As of Jul 16
chart
Previous Close 5.33
Open 5.33
Volume 30,018
3m Avg Volume 60,141
Today’s High 5.36
Today’s Low 5.22
52 Week High 15.38
52 Week Low 4.74
Shares Outstanding (mil) 13.28
Market Capitalization (mil) 187.24
Forward P/E --
Dividend (Yield %) 10.55 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
89
EPS (USD)
FY18
-1.333
FY17
-5.674
FY16
-12.369
FY15
-13.240
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
2.10
5.73
Price to Book (MRQ)
vs sector
1.76
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
45.92
16.72
LT Debt to Equity (MRQ)
vs sector
45.92
12.39
Return on Investment (TTM)
vs sector
-113.12
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Gary Crocker
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Richard Peters
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jean Franchi
Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer, Since 2017
Salary: --
Bonus: --
John Green
Controller, Since 2017
Salary: --
Bonus: --
Ellen Forest
Head of Human Resources, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Kendall Sq Ste B7201
CAMBRIDGE   MA   02139-1670

Phone: +1617.4411000

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

SPONSORED STORIES